Evolution of diabetes insulin delivery devices

Journal of Diabetes Science and Technology

Volumn 4, Issue 3, 2010, Pages 505-513

  Selam, Jean Louis ^a  

^a Diabetes Research Center   (United States)

Author keywords

Continuous subcutaneous insulin infusion; Diabetes; Insulin delivery; Insulin pen; Insulin pump

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

DIABETES MELLITUS; DRUG SELF ADMINISTRATION; ECONOMICS; HUMAN; INSTRUMENTATION; INSULIN INFUSION; METHODOLOGY; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; SYRINGE; UTILIZATION REVIEW;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MEDICATION ADHERENCE; PATIENT PREFERENCE; SELF ADMINISTRATION; SYRINGES;

EID: 78349269200     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400302     Document Type: Conference Paper

References (51)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
3. Selam JL, Charles MA. Devices for insulin administration. Diabetes Care. 1990;13(9):955-79. (Pubitemid 20260735)
4. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig. 2006;26(7):367-401. (Pubitemid 43927053)
5. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med. 2003;20(10):863-6. (Pubitemid 41701510)
6. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev. 2004;20(3):178-88. (Pubitemid 38714315)
7. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab. 2009;11(1):5-19.
8. Bruttomesso D, Filippi A, Costa S. Is there still a place for CSII in the treatment of type 1 diabetes? Comparing CSII with MDI after the arrival of insulin analogues. Infusystems Int. 2008;7(4):25-8.
9. Marcus A. Diabetes care - insulin delivery in a changing world. Medscape J Med. 2008;10(5):120.
10. Selam JL. CSII in Europe: an analysis of articles published in Infusystems International. Infusystems Int. 2007;6(2):14-16.
11. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31(3):430-2.
12. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-62. (Pubitemid 46986681)
13. Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347-57.
14. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-96. (Pubitemid 28343501)
15. Kadiri A, Chraibi A, Marouan F, Ababou MR, el Guermai N, Wadjinny A, Kerfati A, Douiri M, Bensouda JD, Belkhadir J, Arvanitis Y. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998;41(1):15-23. (Pubitemid 28394280)
16. Keith K, Nicholson D, Rogers D. Accuracy and precision of lowdose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43(1):69-74. (Pubitemid 38112268)
17. Korytkowski M, Bell D, Jacobsen C, Suwannasari R, FlexPen Study Team. A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-48. (Pubitemid 37510593)
18. Lee IT, Liu HC, Liau YJ, Lee WJ, Huang CN, Sheu WH. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract. 2009;15(4):699-703.
19. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-25; discussion 1710-11.
20. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22(1):137-40. (Pubitemid 29028310)
21. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27(10):2495-7. (Pubitemid 39281409)
22. Davis EM, Bebee A, Crawford L, Destache C. Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ. 2009;35(5):799-809.
23. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaidenrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29 Spec No:1294-305. (Pubitemid 351172225)
24. Wilk T, Mora PF, Chaney S, Shaw K. Use of an insulin pen by homeless patients with diabetes mellitus. J Am Acad Nurse Pract. 2002;14(8):372-9.
25. Hörnquist JO, Wikby A, Andersson PO, Dufva AM. Insulin-pen treatment, quality of life and metabolic control: retrospective intragroup evaluations. Diabetes Res Clin Pract. 1990;10(3):221-30.
26. Wikby A, Stenström U, Andersson PO, Hörnquist J. Metabolic control, quality of life, and negative life events: a longitudinal study of well-controlled and poorly regulated patients with type 1 diabetes after changeover to insulin pen treatment. Diabetes Educ. 1998;24(1):61-6. (Pubitemid 128460452)
27. Pfützner A, Reimer T, Hohberg C, Frøkjaer LP, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-9.
28. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195-201.
29. Diglas J, Feinböck C, Irsigler K, Winkler F, Egger T, Weitgasser R, Pieber T, Lytzen L. Reduced pain perception with Pen Mate™, an automatic needle insertion device for use with an insulin pen. Pract Diabetes Int. 2005;16(2):39-41.
30. Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S, Lapolla A, Mauri MG, Rossi A, Zappella A. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care. 1992;15(11):1628-30.
31. Zisser H, Jovanovic L. OmniPod Insulin Management System: patient perceptions, preference, and glycemic control. Diabetes Care. 2006;29(9):2175. (Pubitemid 44871205)
32. Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, Klingensmith GJ. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004;113(3 Pt 1):e221-4.
33. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F, AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13 Suppl 1:1-68.
34. DeVries JH, Dayan CM. Indications and current criteria for insulin pump therapy in Europe. Infusystems Int. 2006;5(4):30-2.
35. Potti LG, Haines ST. Continuous subcutaneous insulin infusion therapy: a primer on insulin pumps. J Am Pharm Assoc (2003). 2009;49(1):e1-13.
36. Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Clin Ther. 2007;29 Suppl D:S135-44.
37. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26(4):1142-6. (Pubitemid 36929262)
38. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18 Suppl 1:S14-20. (Pubitemid 34411296)
39. Retnakaran R, Zinman B. Continuous subcutaneous insulin infusion versus multiple daily injections: insights from clinical trials. Infusystems USA. 2006;3(2):9-11.
40. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2009. [Epub ahead of print.]
41. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care. 2004;27(11):2590-6. (Pubitemid 39441456)
42. Retnakaran R, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B. Continuous subcutaneous insulin infusion versus multiple daily injections: modeling predicted benefits in relationship to baseline A1c. Diabetes Care. 2005;28(7):1835-6. (Pubitemid 40923111)
43. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes. 2009;117(5):220-2.
44. Jankovec Z, Rusavy Z. Insulin pump treatment in type 2 diabetes. Infusystems USA. 2008;5(4):29-32.
45. Cope JU, Morrison AE, Samuels-Reid J. Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events. Pediatrics. 2008;121(5):e1133-8.
46. Hanas R, Ludvigsson J. Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents. Pediatr Diabetes. 2006;7 Suppl 4:32-8. (Pubitemid 44122712)
47. Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(5):1150-9. (Pubitemid 44115263)
48. Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152(5):622-8.
49. Conwell LS, Daneman D. Complications of insulin pump therapy in children and adolescents. Infusystems USA. 2008;5(4):25-8.
50. St Charles M, Lynch P, Graham C, Minshall ME. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health. 2008. [Epub ahead of print.]
51. Pickup J. How good is glycaemic control during CSII? Do we still need an artificial pancreas? Infusystems Int. 2006;5(4):25-9.